Shakeela Bahadur

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023 · 128 citations · Full text

Medicine, Oncology, Pharmacology +17

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Hope S. Rugo, Seock‐Ah Im, Gail Lynn Shaw Wright et al. · Journal of Clinical Oncology · 2019 · 80 citations

Medicine, Oncology, Pharmacology +17

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

Jason J. Luke, Manish R. Patel, Erika Hamilton et al. · Journal of Clinical Oncology · 2020 · 51 citations

Medicine, Oncology, Pharmacology +17

A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, Adam S. Asch, Nada Hamad et al. · Blood · 2020 · 25 citations

Medicine, Oncology, Pharmacology +15